JAK2 p.V617F Variants in Non-Blood DNA from Patients with Polycythemia Vera

JAK2 p.V617F Variants in Non-Blood DNA from Patients with Polycythemia Vera

Bibliographic Details
Main Authors:	Naoki Mori, Mari Ohwashi Miyazaki, Kentaro Yoshinaga, Masayuki Shiseki, Junji Tanaka
Format:	Article
Language:	English
Published:	Galenos Publishing House 2023-08-01
Series:	Turkish Journal of Hematology
Subjects:	polycythemia vera essential thrombocythemia jak2 p.v617f mutation
Online Access:	https://jag.journalagent.com/z4/download_fulltext.asp?pdir=tjh&un=TJH-94210

Similar Items

JAK2 V617F prevalence in Brazilian patients with polycythemia vera, idiopathic myelofibrosis and essential thrombocythemia
by: Bárbara da Costa Reis Monte-Mór, et al.
Published: (2007-03-01)

JAK2 Negative Polycythemia Vera
by: Geetha J P., et al.
Published: (2010-07-01)

Data‐driven analysis of JAK2V617F kinetics during interferon‐alpha2 treatment of patients with polycythemia vera and related neoplasms
by: Rasmus K. Pedersen, et al.
Published: (2020-03-01)

Diagnosis of latent polycythemia vera: A clinician’s opinion
by: A L Melikian, et al.
Published: (2016-07-01)

Driver mutations (JAK2V617F, MPLW515L/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera
by: Federico Lussana, et al.
Published: (2017-02-01)

Expression of CD markers in JAK2V617F positive myeloproliferative neoplasms: Prognostic significance
by: Saeid Shahrabi, et al.
Published: (2018-10-01)

Case report: Double L611S/V617L JAK2 mutation in a patient with polycythemia vera originally diagnosed with essential thrombocythemia
by: Xiao-qing Li, et al.
Published: (2022-11-01)

Combination therapy with interferon and JAK1-2 inhibitor is feasible: Proof of concept with rapid reduction in JAK2V617F-allele burden in polycythemia vera
by: M.E. Bjørn, et al.
Published: (2014-01-01)

A mutação JAK2 V617F e as síndromes mieloproliferativas JAK2 V617F mutation and the myeloproliferative disorders
by: Bárbara C. R. Monte-Mór, et al.
Published: (2008-01-01)

Splenomegaly impacts prognosis in essential thrombocythemia and polycythemia vera: A single center study
by: Vincenzo Accurso, et al.
Published: (2019-12-01)

Influence of JAK2V617F allele burden on clinical phenotype of polycythemia vera patients: A study from India
by: Sudha Sazawal, et al.
Published: (2019-01-01)

Can Polycythemia Vera evolve from Acute Myeloid Leukemia? A Case Report Showing a Simultaneous Minor JAK2 V617F Mutated Clone,
by: Beatrice Borsellino, et al.
Published: (2022-06-01)

Ruxolitinib in the treatment of polycythemia vera: patient selection and special considerations
by: Blum S, et al.
Published: (2016-09-01)

Recurrent and Multiple Intracerebral Hemorrhages in Polycythemia Vera Secondary to Myelofibrosis: A Case Report and Literature Review
by: Hidenari Hasui, et al.
Published: (2022-06-01)

Recurrent cerebral venous sinus thrombosis in a young man- A case report of JAK2-negative polycythemia vera
by: Akanksha Singh, et al.
Published: (2019-01-01)

Impact of Anti-Endothelial Cell Antibodies (AECAs) in Patients with Polycythemia Vera and Thrombosis
by: Rossella Cacciola, et al.
Published: (2022-04-01)

Polycythemia vera and management of the thrombotic risk: an update
by: Massimo Franchini
Published: (2023-12-01)

Concurrent Polycythemia Vera with Newly Diagnosed Multiple Myeloma: Case Report and Literature Review
by: Yuan J, et al.
Published: (2023-09-01)

Policitemia Vera en la era del Jak: breve análisis del diagnóstico después de su introducción
by: Norma Fernández Delgado, et al.

Evaluation of JAK2V617F Mutation Prevalence in Myeloproliferative Neoplasm by AS-RT-PCR
by: B Bahar, et al.
Published: (2009-11-01)

Evaluation of JAK2V617F mutation prevalence in Myeloproliferative Neoplasm by AS-RT-PCR
by: H Ghafari, et al.
Published: (2009-09-01)

Red Blood Cell Contribution to Thrombosis in Polycythemia Vera and Essential Thrombocythemia
by: Julien M. P. Grenier, et al.
Published: (2024-01-01)

A remarkable hematological and molecular response pattern in a patient with polycythemia vera during combination therapy with simvastatin and alendronate
by: Anders Lindholm Sørensen, et al.
Published: (2016-01-01)

Ruxolitinib-Associated Infections in Polycythemia Vera: Review of the Literature, Clinical Significance, and Recommendations
by: Parvis Sadjadian, et al.
Published: (2020-10-01)

Recombinant Interferon-β in the Treatment of Polycythemia Vera and Related Neoplasms: Rationales and Perspectives
by: Hans Hasselbalch, et al.
Published: (2022-11-01)

Polycythemia vera: Correlation of JAK2V617F mutation with clinicohematologic characteristics. A single centre experience.
by: Deepti Mutreja, et al.
Published: (2014-08-01)

Detection of JAK2V617F tyrosine kinase mutation and estimation of serum erythropoietin in blood donors who have high hematocrit
by: Haythem A. AL-Rubaie, et al.
Published: (2015-01-01)

EVALUATION OF THE CORRELATION BETWEEN JAK2V617F, LEUCOCYTOSIS AND THROMBOGENIC RISK IN PATIENTS WITH POLYCYTHEMIA VERA AND ESSENTIAL THROMBOCYTHEMIA
by: Antonio Antonov, et al.
Published: (2018-07-01)

How Does 2016 WHO Criteria for Polycythemia Vera Contribute to Our Daily Practice? A Single-Center Study from Turkey
by: Rafet Eren, et al.
Published: (2020-10-01)

Masked polycythemia vera manifested by splanchnic venous thrombosis during pregnancy: a clinical case
by: M. Yu. Nadinskaia, et al.
Published: (2022-05-01)

Histomorphological responses after therapy with pegylated interferon α-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV)
by: Lucia Masarova, et al.
Published: (2017-11-01)

Clinical features of children with polycythemia vera, essential thrombocythemia, and primary myelofibrosis in Japan: A retrospective nationwide survey
by: Hisashi Ishida, et al.
Published: (2020-07-01)

Serum erythropoietin in the evaluation of erythrocytosis: How much does it contribute to the diagnosis of polycythemia vera?
by: Ruchi Gupta, et al.
Published: (2023-01-01)

Cluster-Like Headache Revealing Polycythemia Vera: A Case Report
by: Cyprian Popescu
Published: (2020-06-01)

Quantitative analysis of the erythrocyte membrane proteins in polycythemia vera patients treated with hydroxycarbamide
by: Darshana Kottahachchi, et al.
Published: (2015-06-01)

Systematization of analytical studies of polycythemia vera, essential thrombocythemia and primary myelofibrosis, and a meta-analysis of the frequency of JAK2, CALR and MPL mutations: 2000–2018
by: Mónica Mejía-Ochoa, et al.
Published: (2019-06-01)

Prevalence and clinical outcomes of polycythemia vera and essential thrombocythemia with hydroxyurea resistance or intolerance
by: Kittitat Chiaranairungrot, et al.
Published: (2022-12-01)

Absence of JAK2 V617F-mutated polycythemia vera in obstructive sleep apnea-associated erythrocytosis
by: Stephen E. Langabeer
Published: (2022-12-01)

Isolated cerebellar infarction in a case of JAK 2 mutation-negative polycythemia vera: A case report
by: Prasad Krishnan
Published: (2022-01-01)

In‐Hospital Outcomes of Acute Myocardial Infarction With Essential Thrombocythemia and Polycythemia Vera: Insights From the National Inpatient Sample
by: Jing Wu, et al.
Published: (2022-12-01)